Chongqing Peg-Bio Biopharm Co., Ltd. Is conducting a phase 1b multicenter, open-label study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of a single dose of PN20 in adult patients with primary immune thrombocytopenia (ITP). PN20 is an investigational drug that is administered as a subcutaneous injection. The study is open to adult ITP patients between 18-65 years of age, with a confirmed diagnosis of primary persistent or chronic ITP, who have not achieved a response following either a splenectomy or at least one other standard first line therapy. Participants must also have an average platelet count below 30,000 at least on two occasions, which an overall platelet count below 35,000.
China
Actively Recruiting